Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$27,000.00

Cisplatin-Induced Acute Kidney Injury in Paediatric Cancer Patients

FY 2024-25

Summary
Background: Acute kidney injury (AKI) denotes an abrupt onset of kidney dysfunction which occurs due to various types of kidney tissue damage. Cisplatin (CisP), a chemotherapy, is used to treat many pediatric cancers. CisP nephrotoxicity causes damage to kidney tubule cells via inflammatory, oxidative and vascular injury. AKI may be associated with adverse outcomes years after cancer therapy end, including chronic kidney disease (CKD), cardiovascular disease and death. Earlier AKI detection may enable mitigation of short and long-term kidney damage. Objectives: 1) Derive a pediatric CisP-induced AKI risk score using data from two prospective cohorts; 2) Evaluate validity of the risk score in a retrospective CisP cohort. 3) Evaluate the relation between the AKI risk score and CKD or hypertension (HTN) at 3, 12 and 36 months after CisP treatment end. Methods: Design/Cohorts: I will use data from two child CisP cohorts: ABLE (includes children with cancer receiving CisP; study complete; n=159) and ACCENT (ongoing; n=~ 50). Variables from both studies will be combined. The merged cohort will be the development dataset to develop the base model (logistic regression). The validation dataset will be the KINDEST SickKids cohort (cohort of children treated for cancer at SickKids from 2016-2020; n= ~100); I will evaluate AKI prediction, calibration and other performance measures. Significance: Many metabolomic and protein biomarkers are being studied to achieve early CisP-AKI diagnosis but are far from clinical application. This risk score may a) help diagnose CisP-AKI early (enabling early AKI prevention and injury mitigation; improve long-term kidney health); b) be applied in clinic or research; and c) help provide a benchmark for novel biomarker predictive studies.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
529888
Name
Haddad Sham
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Cisplatin-Induced Acute Kidney Injury in Paediatric Cancer Patients
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Acute Kidney Injury (Aki); Chemotherapy; Chronic Kidney Disease (Ckd); Epidemiology; Hypertension; Nephrology; Nephrotoxicity; Oncology; Pediatrics; Predictive Modelling
Abstract
Background: Acute kidney injury (AKI) denotes an abrupt onset of kidney dysfunction which occurs due to various types of kidney tissue damage. Cisplatin (CisP), a chemotherapy, is used to treat many pediatric cancers. CisP nephrotoxicity causes damage to kidney tubule cells via inflammatory, oxidative and vascular injury. AKI may be associated with adverse outcomes years after cancer therapy end, including chronic kidney disease (CKD), cardiovascular disease and death. Earlier AKI detection may enable mitigation of short and long-term kidney damage. Objectives: 1) Derive a pediatric CisP-induced AKI risk score using data from two prospective cohorts; 2) Evaluate validity of the risk score in a retrospective CisP cohort. 3) Evaluate the relation between the AKI risk score and CKD or hypertension (HTN) at 3, 12 and 36 months after CisP treatment end. Methods: Design/Cohorts: I will use data from two child CisP cohorts: ABLE (includes children with cancer receiving CisP; study complete; n=159) and ACCENT (ongoing; n=~ 50). Variables from both studies will be combined. The merged cohort will be the development dataset to develop the base model (logistic regression). The validation dataset will be the KINDEST SickKids cohort (cohort of children treated for cancer at SickKids from 2016-2020; n= ~100); I will evaluate AKI prediction, calibration and other performance measures. Significance: Many metabolomic and protein biomarkers are being studied to achieve early CisP-AKI diagnosis but are far from clinical application. This risk score may a) help diagnose CisP-AKI early (enabling early AKI prevention and injury mitigation; improve long-term kidney health); b) be applied in clinic or research; and c) help provide a benchmark for novel biomarker predictive studies.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Haddad, Sham
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~